Adamis Pharmaceuticals (NASDAQ:ADMP) Announces Quarterly Earnings Results

Adamis Pharmaceuticals (NASDAQ:ADMP – Get Rating) announced its quarterly earnings results on Monday. The specialty pharmaceutical company reported ($0.07) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.03) by ($0.04), Fidelity Earnings reports. Adamis Pharmaceuticals had a negative net margin of 458.77% and a negative return on equity of 85.31%.

NASDAQ:ADMP opened at $0.43 on Wednesday. The firm’s fifty day simple moving average is $0.50 and its 200 day simple moving average is $0.64. Adamis Pharmaceuticals has a twelve month low of $0.31 and a twelve month high of $1.48.

A number of equities analysts have weighed in on the stock. StockNews.com assumed coverage on shares of Adamis Pharmaceuticals in a report on Saturday. They issued a “sell” rating on the stock. Zacks Investment Research lowered shares of Adamis Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, January 19th.

Several large investors have recently bought and sold shares of ADMP. Millennium Management LLC increased its stake in Adamis Pharmaceuticals by 3,449.4% during the 3rd quarter. Millennium Management LLC now owns 557,157 shares of the specialty pharmaceutical company’s stock worth $540,000 after buying an additional 541,460 shares during the period. JPMorgan Chase & Co. increased its stake in Adamis Pharmaceuticals by 735.2% during the 4th quarter. JPMorgan Chase & Co. now owns 218,573 shares of the specialty pharmaceutical company’s stock worth $132,000 after buying an additional 192,403 shares during the period. State Street Corp increased its stake in Adamis Pharmaceuticals by 13.1% during the 1st quarter. State Street Corp now owns 475,373 shares of the specialty pharmaceutical company’s stock worth $271,000 after buying an additional 55,168 shares during the period. Finally, Virtu Financial LLC increased its stake in Adamis Pharmaceuticals by 9.6% during the 4th quarter. Virtu Financial LLC now owns 224,561 shares of the specialty pharmaceutical company’s stock worth $136,000 after buying an additional 19,691 shares during the period. Institutional investors and hedge funds own 9.52% of the company’s stock.

Adamis Pharmaceuticals Company Profile (Get Rating)

Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy, opioid overdose, respiratory, and inflammatory disease in the United States. The company's product candidates comprise SYMJEPI epinephrine pre-filled syringe injectable products for use in the emergency treatment of acute allergic reactions, including anaphylaxis; dry powder inhaler products for the treatment of asthma; and naloxone injection for the treatment of opioid overdose.

Featured Articles